• MediGene AG has initiated a clinical Phase I/II trial of the drug candidate NV1020 for the treatment of liver metastases developing from colorectal cancer. NV1020 is a herpes simplex virus, genetically modified for the specific destruction of tumor cells without harming healthy tissue.
  • Sangart has initiated a Phase II clinical trial involving MP4 (Hemospan), a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions.
  • Corautus Genetics has begun its Phase IIb clinical trial to evaluate the safety and efficacy of Vascular Endothelial Growth Factor-2 (VEGF-2) for the treatment of severe cardiovascular disease.
  • Encysive Pharmaceuticals has completed enrolling 240 patients in the company's multicenter, Phase III STRIDE-2 (Sitaxsentan To Relieve ImpaireD Exercise) trial to evaluate the safety and efficacy of sitaxsentan (Thelin) in patients with pulmonary arterial hypertension.
  • Genentech and OSI Pharmaceuticals have initiated a Phase IIIB clinical study of the investigational therapy erlotinib HCl (Tarceva) in patients with second- and third-line non-small cell lung cancer who have previously received chemotherapy.
  • AstraZeneca is recruiting patients for a new clinical trial for non-small-cell lung cancer. The INTEREST (IRESSA Non-small-cell lung cancer Trial Evaluating REsponse and Survival against Taxotere) trial will evaluate the effectiveness of the oral anti-cancer agent gefitinib (IRESSA) tablets vs. docetaxel (Taxotere) in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum-based chemotherapy.
  • Threshold Pharmaceuticals has received a Special Protocol Assessment from the FDA for a pivotal Phase III clinical trial to evaluate Glufosfamide in patients with metastatic pancreatic cancer refractory to first-line treatment.